---
title: "Titanium and refractory metal powders producer Amaero postpones $53 million Nasdaq cross-listing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300008721.md"
description: "Titanium and refractory metal powders producer Amaero postpones $53 million Nasdaq cross-listing"
datetime: "2026-09-24T09:48:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300008721.md)
  - [en](https://longbridge.com/en/news/300008721.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300008721.md)
generator: "portal-rs"
---

# Titanium and refractory metal powders producer Amaero postpones $53 million Nasdaq cross-listing

Amaero, a producer of titanium and refractory metal powders for defense and aerospace 3D printing, postponed its IPO on Wednesday, citing adverse market conditions. It had filed to raise $53 million by offering 7.5 million shares at $7.06, the as-converted September 11 close of its shares on the Australian Securities Exchange (3DA).

The McDonald, TN-based company was founded in 2013 and booked $12 million in revenue for the 12 months ended June 30, 2026. It had planned to list on the Nasdaq under the symbol AMRO. Stifel and Baird were set to be the joint bookrunners on the deal.

### Related Stocks

- [3DA.AU](https://longbridge.com/en/quote/3DA.AU.md)
- [AMRO.US](https://longbridge.com/en/quote/AMRO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [How Investors May Respond To Industrivarden Stock After A Third Quarter Net Loss](https://longbridge.com/en/news/301485725.md)
- [Ledger wallet tampering suspected after reports of crypto thefts](https://longbridge.com/en/news/301487263.md)
- [GoodVision AI, post-merger with Calisa Acquisition, exhibits at TechCrunch Disrupt 2026](https://longbridge.com/en/news/301494959.md)
- [Genentech, Inc. FDA Accepts BLA for Vamikibart in UME; 52-Week Phase III Data Shown](https://longbridge.com/en/news/301490507.md)
- [Hedera: Agent Accounts launch targets mainnet availability - Q2 2027](https://longbridge.com/en/news/301487589.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**